| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df02dc2eab1779ebc7dfb5accf94318b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70503 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2017-01-03^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_317471a0f87d0a71a17b042be8ae7d33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_859a56f273c9e7ae49f6f8da0d02012d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b5c214d002bc3dfeddc2a26eb991592
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_809dbd23204a8eff78f93bf9cc7367f1 |
| publicationDate |
2018-11-14^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3400443-A1 |
| titleOfInvention |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma |
| abstract |
The present invention relates to a method for predicting the survival time of a subject suffering from renal cell carcinoma comprising the steps of: i) quantifying the percent of CD8+ T cells co-expressing PD-1 and Tim-3 in a tumor tissue sample obtained from the subject, ii) comparing the percent quantified at step i), with its corresponding predetermined reference value and iii) concluding that the subject will have a short survival time when the percent of CD8+ T cells co-expressing PD-1 and Tim-3 is higher than its corresponding predetermined reference value or concluding that the subject will have a long survival time when the percent of CD8+ T cells co-expressing PD-1 and Tim-3 is lower than its corresponding predetermined reference value. |
| priorityDate |
2016-01-04^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |